The Andersons, Inc. posted a record third-quarter net income of $46 million, or $1.36 per diluted share, boosted by strong performance in its Renewables and Agribusiness segments. Renewables achieved a record pretax income of $63 million due to efficient operations and higher co-product values, while Agribusiness saw improved results from market volatility and higher commodity prices. The company is optimistic about future growth, with ongoing projects like the Port of Houston soybean meal export and ethanol capacity expansion in Indiana. It also benefits from $27 million in 45Z tax credits related to low-carbon strategies, positioning it well for long-term value creation.
The Andersons, Inc. third-quarter results provide context for readers. For those following US stocks on Pluang, 67 out of 150 priced stocks rose while 83 fell. Notable movers include Moderna, Inc. (MRNA) at USD 231.88 with a 1-day change of +5.01%, Firy Inc. (FIRY) at USD 12.40 down 4.62%, and AMC Entertainment Holdings, Inc. (AMC) at USD 3.33 up 4.55%. This data is as of Nov 04, 2026 01:41 WIB.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
